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after external beam radiotherapy (EBRT).
METHODS: Forty-two patients with biopsy-proven recurrence were enrolled on a Phase II study
of salvage HDR monotherapy using iridium-192. Median pretreatment EBRT dose was 8100 cGy
(6840e8640 cGy) and the median time from completion of EBRT to salvage HDR was 73 months.
The protocol prescription dose of 3200 cGy was delivered in four fractions over 30 hours in a single
insertion. Median followup after salvage HDR was 36 months (6e67 months).
RESULTS: The actuarial prostate-specific antigen biochemical relapse-free survival and distant
metastases-free survival rates at 5 years were 68.5% and 81.5%, respectively. Cause-specific sur-
vival was 90.3%. Late genitourinary Grade 1and 2 toxicities were found in 38% and 48%, respec-
tively, and one patient developed Grade 3 urinary incontinence. Late Grade 1 and 2 gastrointestinal
toxicity was noted in 17% and 8% of patients, respectively. Three patients (7%) developed Grade 2
late urinary toxicity (urethral stricture), which were corrected with urethral dilatation, and one pa-
tient developed Grade 3 urinary incontinence. No Grade 4 toxicities were observed.
CONCLUSIONS: Genitourinary toxicity was the most commonly encountered toxicity observed
after salvage HDR but severe toxicities were uncommon. Salvage HDR is an effective and well-
tolerated modality for locally recurrent prostate cancer and should be considered even for patients
who have previously been treated with ultra-high dose levels of EBRT.  2014 American Brachy-
therapy Society. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Keywords: Salvage brachytherapy; High dose rate brachytherapyIntroduction
High-dose intensity-modulated radiotherapy (IMRT)
has proven to be an effective treatment for localized pro-
state cancer (1e6). In the case of local recurrence, sal-
vage options are limited for these patients. These patients
are often not considered optimal candidates for salvagest 2013; received in revised form 31 October 2013;
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.1016/j.brachy.2013.11.005prostatectomy because of their age or medical comorbid-
ities even if the disease presentation at the time of recur-
rence demonstrates localized disease only. Prior definitive
dose levels of radiation to the bladder, rectal wall, and
urethra place these patients at higher risk for severe compli-
cations with additional salvage therapy. High-dose-rate
brachytherapy (HDR) has dosimetric and radiobiologic ad-
vantages as a salvage treatment paradigm. One recent study
(7) reported 50% biochemical tumor control outcomes with
salvage HDR brachytherapy when used as monotherapy.
We report on the long-term results of a prospective Phase
II trial where HDR brachytherapy was used as salvage ther-
apy for localized recurrent disease after external beam
radiotherapy (EBRT).. Open access under CC BY-NC-ND license.
Table 1
Dosimetry
Dosimetry factors Minimum
Lower-
hinge Median
Upper-
hinge Maximum
Prostate volume (cm3) 17 28 33.5 43 64
V100 (%) 87 92 94.5 96 99
D90 (%) 90 103 106.5 108 119
V150 (%) 23 29 32.5 38 46
Urethra Dmax 110 114 116 118 127
Urethra D5 (%) 104 110 113 115 122
Urethra D20 (%) 100 108 110.5 113 119
Rectum V100 cm
3 0 0 0 0 0.1
Rectum D1 cm
3 (%) 18 50 61.5 72 86
Rectum D2 cm
3 (%) 14 45 54 63 79
Table 2
Patient characteristics
Characteristics Patient (n 5 42) I
Median months followup (range) 36 (2e66)
Median patient age (range) 72 (56e83)
Median cm3 pretreatment gland volume (range) 33.5 (11e64)
Pretreatment PSA (%)
!4.0 23 (55)
4.0e10 14 (33)
O10 5 (12)
Gleason score (%)
6 3 (7)
7 25 (60)
$8 14 (33)
Patient on ADT (%) 18 (43)
PSA 5 prostate-specific antigen; ADT 5 androgen-deprivation
therapy.
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Forty-two patients with biopsy-proven recurrence were
enrolled on an institutional review boardeapproved Phase
II study of salvage HDR monotherapy using iridium-192.
The primary end points of the trial were toxicity, assessed
with the Common Toxicity Criteria for Adverse Events
version 3, as well as the International Prostate Symptom
Score (IPSS), and the International Index of Erectile Func-
tion. Biochemical control was evaluated using the Phoenix
definition (nadir þ2). Patient accrual spanned from 2007 to
2011, and patients were followed for at least 1 year after
treatment on protocol and then in routine followup there-
after. Patients were seen in followup 1 month after treat-
ment and then at 4-month intervals.
To be eligible for the trial, patients were required to have
biopsy-proven recurrence after definitive EBRT. All bi-
opsies were confirmed by pathologic review at our institu-
tion. Patients with radiographic evidence of extraprostatic
disease demonstrated on an MRI with an endorectal coil,
or metastatic disease seen on bone scan, were excluded
from the study. Other exclusion criteria included patients
with serum prostate-specific antigen (PSA)O10 ng/mL at
the time of assessment and those with a baseline total IPSS
O15 before planned salvage therapy. Any patient with a
history of inflammatory bowel disease or rectal surgery
was also excluded from enrollment. Patients were also
required to be able to tolerate general anesthesia. Those
with abnormal coagulation profiles (international normal-
ized ratioO2.5, platelet count!75,000) or liver/renal func-
tion testsO1.5  normal were also ineligible.
The method of HDR used in these patients has been pre-
viously described (8). In short, HDR catheters were placed
with ultrasound guidance under general anesthesia. The
entire prostate was implanted. The clinical target volume
was the entire prostate, with a margin of 5 mm added around
the entire gland. A dose of 800 cGy per fraction was pre-
scribed to the periphery of the clinical target volume, except
near the bladder neck, were the dose was typically 5e10%
lower, at the discretion of the treating oncologist, unless
tumor was thought to reside in that area. Four fractions were
given a minimum of 4 hours apart, over 30 hours, in a single
insertion. A genetic inverse treatment-planning algorithm
was used for treatment-planning source dwell position and
time optimization. The following doseevolume constraints
were used for treatment planning similar to our dose thresh-
olds used when treating non-recurrent HDR patients: mini-
mum 95% target coverage with the prescription dose (PD),
120% of PD for maximum urethra dose, and rectal
maximum dose not greater than 100% of PD. Catheter po-
sition was verified radiographically before each fraction.
An iridium-192 HDR source was used for each treatment,
using an afterloading technique. Table 1 summarizes key
dosimetric parameters achieved for this study.
These 42 patients had a median followup of 36 months,
with a range of 6e66 months. Patient characteristics aresummarized in Table 2. Median pretreatment EBRT dose
was 8100 cGy (6840e8640 cGy) and the median time from
completion of initial EBRT to salvage HDR was 78 months.
Median presalvage PSAwas 3.54 ng/mL. Eighteen patients
had received androgen-deprivation therapy before salvage
HDR, but androgen-deprivation therapy was discontinued
after treatment in all cases.Results
Tumor control outcomes
Ten patients developed a biochemical relapse at a me-
dian of 16.5 months from salvage treatment. The actuarial
PSA relapse-free survival at 5 years was 68.5% (Fig. 1).
Three patients have developed evidence of metastatic dis-
ease. The actuarial distant metastases-free survival at 5
years was 81.5% (Fig. 2), and the 5-year overall survival
outcome was 79%.
Toxicity outcomes
Acute genitourinary (GU) Grade 1 and 2 toxicities were
noted in 38% and 40% of patients, respectively. Late GU
Grade 1 and 2 toxicities were observed in 38% and 48%,
Fig. 1. PSA relapse-free survival. PSA5 prostate-specific antigen;
HDR5 high-dose-rate brachytherapy.
Fig. 2. Distant metastases-free survival. HDR5 high-dose-rate brachy-
therapy.
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incontinence. Three patients developed urethral stricture
(Grade 3), which were corrected with urethral dilatation.
The median time to develop Grade 3 complications was 9
months (range, 9e12 months), and the median time for res-
olution of Grade 3 symptoms was 7 months (range, 23e21
months). No Grade 4 urinary toxicities were observed.
Baseline urinary status was found to be significantly asso-
ciated with post-treatment late urinary toxicity for the devel-
opment of Common Toxicity Criteria for Adverse Events
Grade 2 ( p 5 0.008) but not for Grade 3 or higher toxicity.
Figure 3 illustrates the rates of Grade 2 GU toxicity based on
baseline scores. Seventy-eight percent of patients were
without significant urinary symptoms (GU Grade 0e1)
before the administration of salvage treatment, and 52% of
these remained free of additional urinary toxicity at the time
of last followup. Thus, the majority of urinary toxicity
resolved to baseline. Of the three patients who developed
Grade 3 urinary toxicity, two were characterized at baseline
as having Grade 2 symptoms, and one patient was classified
as having Grade 1 symptoms at baseline. Themedian IPSS at
baseline was 6 (range, 1e17), and the median IPSS at last
followup was 12 (range, 1e30). Resolution of an elevated
IPSS was seen in 41% of patients (returned within 2 points
of baseline) within a median time of 4.5 months. IPSS did
not return to baseline values at the time of last followup in
24 patients, with a reported median IPSS value of 14.5 at
the time of last followup (range, 5e30).
Late Grade 1 and 2 gastrointestinal (GI) toxicities were
noted in 43% and 14% of patients, respectively, and 83% of
patients were free of Grade 2 or higher GI complications
(Fig. 3). GI complications consisted almost entirely of tran-
sient rectal bleeding. No Grade 3 or higher GI complica-
tions were encountered.The majority of patients were not sexually active at
baseline. The median International Index of Erectile Func-
tion score before and after treatment was 2 and 1.5,
respectively.
No dosimetric values such as V100 (volume of the pros-
tate receiving PD) or D90 (dose to 90% of the prostate
exposed to PD) were significantly associated with the risk
of disease progression or any complications.Discussion
In this prospective study of salvage HDR monotherapy,
76% of patients were able to achieve biochemical control
in a patient population that is by definition radioresistant.
Our data suggest that reirradiation with high-dose hypofrac-
tionation may be a rational salvage approach to eradicate
tumor cells that have survived conventionally fractionated
radiotherapy. We also noted an excellent tolerance profile
to patients who received salvage HDR despite the high
initial doses that patients had received as part of their defin-
itive EBRT. The most frequently encountered complication
was in the GU domain, with a median post-treatment IPSS
score of 12, compared with a baseline IPSS of 6 for the
entire cohort. Grade 3 complications were infrequent, and
all such cases eventually had resolution of these effects
with minor surgical intervention. It is important to note that
no severe GI complications were encountered in this cohort,
despite having had previous very high doses of EBRT.
Local recurrence after definitive EBRT is not infrequent.
It has been estimated that nearly one-third of patients who
undergo EBRTwill have positive post-treatment biopsies of
the prostate, and 15% of patients who received 8100 cGy
were found to have positive biopsies (9). The consequences
Fig. 3. Grade 2 GI and Grade 2 GU toxicityefree toxicity survival curve. GI5 gastrointestinal; GU5 genitourinary; HDR5 high-dose-rate brachytherapy.
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icant. In a report of the outcomes of locally recurrent pros-
tate cancer after EBRT, Kuban et al. reported that nearly
one-third of patients suffered from major complications
associated with local recurrence (10). Locally recurrent dis-
eases pose as well a significant risk for the development of
distant metastases (1, 9, 11).
Often patients who have developed locally recurrent dis-
ease after radiotherapy are not candidates for salvage pros-
tatectomy due to age or coexisting medical comorbidities.
Salvage prostatectomy also carries a significant risk of
rectal injury (16e58%), and 68% of patients will require
the use of at least one pad for urinary incontinence (12).
Long-term followup suggests that up to 54% of patients
who undergo salvage prostatectomy will achieve biochem-
ical control of their disease (13).
The use of other salvage modalities such as cryoablation
after failed radiotherapy has been reported. In a large study
of quality of life, 72% of patients reported incontinence at
a median of 17 months, and two-thirds of patients reported
significant urinary symptoms (14). Rectal injury rates of
2% and incontinence rates between 4% and 8% have been re-
ported. The fistula rate was 3.4% (15). In a large study of
salvage cryotherapy, 17% of patients were noted to positive
biopsies after treatment (16). Therefore, effective treatment
options without significant morbidity in the setting of locally
recurrent prostate cancer after radiotherapy are limited.
The results of low-dose-rate salvage brachytherapy have
also been reported. Reports published over 10 years ago
(17, 18) have indicated that while tumor control can be
achieved with low-dose-rate salvage brachytherapy in
30e50% of patients, toxicity outcomes were increased
possibly related to the use of less sophisticated planning
techniques or the selection of less optimal patients based
on the presence of baseline symptoms.
More recently Chen et al. (7) have described preliminary
outcomes of MRI-based partial prostate salvage low-dose-
rate brachytherapy in 15 patients with a median followup
of 23 months (8e88 months), with no cases of Grade 3or higher GU complications. Biochemical control was
achieved in 73% of patients at 3 years.
Aaronson et al. have reported outcomes for 24 patients
who underwent low-dose-rate brachytherapy for recur-
rences after 66e70.2 Gy of EBRT. Biochemical control
was observed in 88% of patients with a median followup
of 30 months (19). Burri et al. have reported the outcomes
of 37 patients with a median followup of 87 months who
underwent low-dose-rate salvage brachytherapy. At 5-year
followup, 65% of patients were found to have achieved
biochemical freedom from failure (Phoenix definition),
and 57% remained free of biochemical failure at 10 years.
Grade 3 or 4 toxicity was noted in 11% of patients, consist-
ing of transurethral resection of the prostate (TURP) in 2
patients, hematuria requiring fulguration in one patient,
and one case of prostatorectal fistula (20).
Several aspects unique to HDR brachytherapy make it
ideally suited for use as a salvage procedure.
 Brachytherapy delivers high-dose radiation directly to
the target tissue. In the case of EBRT, radiation must
pass through skin, muscle, bone, bowel, and other soft
tissues to reach the prostate. Thus, in the setting of
previously irradiated patients, HDR brachytherapy
can deliver radiation without repeating significant
exposure to these surrounding tissues.
 HDR brachytherapy results in very little treatment-
related uncertainty. Organ motion is eliminated with
HDR brachytherapy. Because post-implant CT-based
three-dimensional dosimetry is used for treatment
planning, the exact position of critical structures such
as the rectum, bladder, and urethra are known and
predictable. Thus, there is no uncertainty regarding
the dose of radiation given to these structures, as well
as the prostate.
 By taking advantage of the inverse dose fall-off
phenomenon, areas within the prostate can be differen-
tially treated to higher or lower doses. HDR brachy-
therapy uses computer-optimized treatment planning.
Table 3
Outcomes of salvage treatments
Author Year Modality N
Followup
(mo) Outcome Grade 3e4 toxicity
Vaidya (23) 2000 RP 6 27 83% 3-year FFP 0%
Bianco (12) 2005 RP 100 60 55% 5-year FFP 13e33%
Izawa (24) 2002 Cryotherapy 131 58 40% 5-year bNED NR
Ismail (25) 2007 Cryotherapy 100 34 59% 3-year bNED NR
Bahn (26) 2012 Cryotherapy 73 44 75% negative biopsy
Grado (17) 1999 LDR 49 64 34% 5-year bNED 3%
Beyer (18) 1999 LDR 17 62 53% 5-year FFP 16%
Wong (27) 2006 LDR 17 44 75% 4-year bNED NR
Allen (28) 2007 LDR 12 45 63% 4-year bNED 47%
Nguyen (29) 2007 LDR 25 47 70% 4-year bNED 0%
Lee (30) 2008 LDR 21 36 38% 5-year bNED 30%
Aaronson (19) 2009 LDR 24 30 88% 3-year bNED 0%
Burri (20) 2009 LDR 37 86 54% 10-year bNED 11%
Chen (7) 2013 HDR 52 60 51% 5-year bNED 4%
Present series 2013 HDR 42 38 70% 3-year bNED 8%
RP 5 radical prostatectomy; FFP 5 freedom from progression; bNED 5 biochemical non-evidence of disease; LDR 5 low-dose-rate brachytherapy;
NR 5 not reported.
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reduce dose while emphasizing the dose to potential
tumor-bearing areas.
 HDR brachytherapy is well suited to hypofractionated
treatment schedules. Prostate cancer is thought to
respond favorably to large amounts of radiation given
in a limited number of treatments.
In addition, a patient-based dosimetric comparison be-
tween stereotactic body radiotherapy and HDR brachyther-
apy found that EBRTwas not able to achieve either the high
doses to the prostate or the dose-sparing effect on normal
tissues that HDR brachytherapy is able to achieve (21),
underscoring the advantages of HDR over external beam
techniques.
The results of the University of California San Francisco
(UCSF) salvage HDR experience have been recently
updated (7). In this retrospective analysis, 52 consecutive
patients received 36 Gy in six fractions, given in two inser-
tions, 1 week apart. With a median followup of 60 months,
51% of patients were found to be biochemically free of
relapse at 2 years, and only two patients developed Grade
3 or higher GU toxicity using CTAE criteria. An initial
report published in 2007 reported 14% Grade 3 complica-
tions in 21 patients with a median followup of 19 months
(22), suggesting that, with further time, Grade 3 complica-
tions tend to improve.
The results of the USCF experience as well as the cur-
rent report have used dose-fractionation schedules with
similar biologic effective doses (170e180 Gy, assuming
an a/b of 1.5 Gy) with acceptable toxicity and tumor con-
trol, suggesting that either 36 Gy in six fractions with two
insertions, or 32 Gy in four fractions in a single insertion,
would be appropriate fractionation schedules to consider.
However, the optimal dose-fractionation schedule for
salvage HDR brachytherapy has yet to be elucidated.As illustrated in Table 3, the outcomes of the present
study compare favorably with results in the literature.
HDR brachytherapy is an excellent treatment for salvage
because it provides the high doses for hypofractionation
while maintaining low doses to the urethra, bladder, and
rectum. Because HDR brachytherapy is able to provide
high-dose gradients that provide meaningful sparing of
normal tissue between intimately juxtaposed structures
such as the prostate and rectum that even stereotactic body
radiation with the latest imaging and treatment delivery
techniques cannot match, treatment was well tolerated with
high rates of local control.
Conclusion
This prospective study of HDR salvage monotherapy
demonstrates that it is an effective and well-tolerated treat-
ment paradigm for patients who develop locally recurrent
prostate cancer EBRT. HDR brachytherapy should be
considered in the local management of recurrent prostate
cancer, even in patients who have been previously heavily
treated with ultra-high-dose EBRT.
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